top of page
News, Events and Updates
Search
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)
Dec 19, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 9, 2023
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 14, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 23, 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 31, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results
May 10, 2022
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Mar 15, 2022
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Aug 12, 2021
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
